What did @coachdjvanillaface actually say?
The creator laid out a progression framework for people already on TRT who want to "optimize results." The core argument: before stacking anabolic steroids, you should first push your testosterone dose into supraphysiological territory to understand your personal side effect profile, specifically your sensitivity to DHT conversion and estrogen. He also floated peptides and thyroid axis manipulation as intermediate steps between lifestyle optimization and full steroid stacking. His closing line was essentially: "start bumping it up and assessing from there before you start adding secondary compounds."
The framing is methodical, almost clinical. He's not saying "take more drugs." He's saying take more testosterone specifically first, then decide. That distinction matters, but it also carries real risks that go unaddressed.
Does the science back this up?
Partially, yes. The logic of understanding your individual hormonal response before layering compounds has some grounding in pharmacology. But the evidence base for the specific progression he describes is thin, and several of his intermediate recommendations are either unvalidated or actively contested.
On the testosterone side, the dose-response relationship between serum testosterone and outcomes like muscle hypertrophy and fat loss is reasonably well established. Bhasin et al. (2001, NEJM) demonstrated a clear dose-dependent effect on lean mass and strength in healthy men across a wide testosterone range, including supraphysiological levels. So the idea that pushing into higher serum levels produces meaningful changes is supported. What's not supported is the idea that doing so is a safe or medically appropriate diagnostic step for determining steroid candidacy.
On thyroid axis manipulation for fat loss, the evidence is far weaker. Using thyroid hormones in euthyroid individuals, meaning people with normal thyroid function, to enhance fat loss lacks robust clinical trial support and carries documented cardiovascular and bone density risks (Bauer et al., 2020, Thyroid). Recommending TSH/T3/T4 testing is reasonable. Implying thyroid manipulation is a sensible "pharmaceutical method" for fat loss in otherwise healthy people on TRT is a stretch that the data does not support.
What did they get wrong (or right)?
He got the SHBG and free testosterone point right. Total testosterone alone is a genuinely incomplete picture, and clinicians increasingly agree on this. Travison et al. (2017, JCEM) confirmed that free testosterone calculated from SHBG provides meaningful additional information beyond total T, particularly in older men and those with metabolic syndrome. Credit where it's due.
He got the "assess DHT and estrogen response before stacking" logic approximately right in principle, but wrong in execution. The actual clinical reason to monitor DHT and estradiol is to manage side effects like erythrocytosis, prostate impact, and cardiovascular strain, not primarily to serve as a selection criterion for which anabolic compound to use next. Framing it as a "predisposition analysis" for steroid stacking is a consumer-friendly gloss on a genuinely complex clinical question.
The peptide mention deserves scrutiny. He references peptides as a "non-androgenic route" without naming specific compounds or acknowledging the serious regulatory and safety issues surrounding compounded peptides. Many peptides discussed in fitness communities lack FDA approval and have limited human clinical trial data. This is a real gap in his presentation.
- Correct: SHBG and free T matter more than total T alone
- Correct: Dose escalation before stacking has some pharmacological logic
- Misleading: Thyroid axis manipulation framed as a reasonable fat loss tool
- Incomplete: Peptide recommendation with no safety or regulatory context
- Problematic: Supraphysiological testosterone framed as a diagnostic step rather than a risk
What should you actually know?
Supraphysiological testosterone is not a diagnostic tool. It is an off-label, unsupervised hormonal escalation with documented risks including erythrocytosis, left ventricular hypertrophy, dyslipidemia, and suppression of endogenous hormone axes that may not recover. Baggish et al. (2017, Circulation) found structural cardiac changes in long-term anabolic steroid users, including those who started with testosterone alone. The fact that someone is already on TRT does not make escalation into supraphysiological ranges a benign experiment.
Legitimate TRT, the kind managed by a licensed provider, targets restoration of normal physiological levels, typically 400 to 700 ng/dL depending on the clinical context, not optimization for performance. The creator's framing blurs the line between therapeutic hormone replacement and performance enhancement in ways that could push viewers toward decisions their prescribing clinicians are not aware of and have not approved.
If you are on TRT and considering changes, that conversation belongs with your prescriber. Bloodwork monitoring, including comprehensive metabolic panels, hematocrit, lipids, and PSA, is not optional at higher doses. It is the floor, not the ceiling, of responsible management.